Moderna's Road To Stopping The Red

TG Therapeutics: Subcutaneous Briumvi Data A Key Near-Term Catalyst

Fast Drug Launch For Madrigal Pharmaceuticals Brings Buyout Discussion

Nkarta, Inc.: Trying To Find Space In A Crowded Place

Altimmune Could Find A Partner For Its Phase 3 Exercise

Iovance Biotherapeutics: Amtagvi Launch Growing, But Stock Isn't

Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January

Cassava Sciences: REFOCUS Unlikely To Save Simufilam, Careful Development Needed

Multiple Catalysts Ahead For Nektar Therapeutics

Allakos Runs Up Into A Near-Term Catalyst

Nkarta: Catalysts Ahead, But Competition In Cell Therapy Too (Rating Downgrade)

Regulatory And Clinical Catalysts Ahead For Altimmune

Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder

Zymeworks Approaching A Moment Of Truth With Zanidatamab

Aurinia Pharmaceuticals: This Recovery Can Continue

Moment Of Truth Approaches For Pyxis Oncology

Terns Pharmaceuticals: Weight Loss Drug TERN-601 Is Competitive

Cassava Sciences: Volatility Provides Trading Opportunities

Verona Pharma Is Launching Ohtuvayre, Although There Will Be Competition

Iovance Biotherapeutics: Amtagvi Launch Continues Upward

Moment Of Truth Approaches For Moderna's RSV Vaccine

Recent Run-Up Provides MAIA Biotechnology With Breathing Room

Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway

Agenus: Multiple Milestones In The Second Half Of 2024

Altimmune's Pemvidutide Is Not To Be Dismissed